Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Multiple Dosing Study in Asymptomatic GRN-frontotemporal Dementia Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001

Next Previous
X
Search
Trial Profile

Open-label Multiple Dosing Study in Asymptomatic GRN-frontotemporal Dementia Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VES 001 (Primary)
  • Indications Frontotemporal dementia
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Acronyms SORT-IN-2
  • Sponsors Vesper Bio

    • Most Recent Events

    • 07 Jan 2025 According to a Vesper Bio media release, the first patient has now been enrolled and Vesper expects to have completed enrolment and dosing by mid-2025. It will be performed at one clinical center in the Netherlands at Erasmus University Medical Centre, Rotterdam, the Netherlands, under Principal Investigator (PI) Professor Harro Seelaar and another in the United Kingdom the Leonard Wolfson Experimental Neurology Centre clinical research facility, under Professor Jonathan Rohrer.
    • 18 Dec 2024 Planned End Date changed from 5 Aug 2025 to 5 Sep 2025.
    • 18 Dec 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top